Get started Log in

ORY — ORYZON Genomics SA News Story

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Market Cap
€208.83m
Enterprise Value
€199.99m
Revenue

Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment

ORYZON Genomics SA

28/09/2026 07:25

BRIEF-Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS TreatmentSept 28 (Reuters) - Oryzon Genomics SA ORY.MC:
RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL TO INITIATE HOPE-2 PHASE II STUDY OF VAFIDEMSTAT FOR PMS (PHELAN– MCDERMID SYNDROME) TREATMENT
Source text
Further company coverage: ORY.MC

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

Recent news on ORYZON Genomics SA

Brief: Oryzon Gets New Patent Grants For Vafidemstat In Four Countries
15/10/2026 07:06
Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
28/09/2026 07:25
Spanish stocks - Factors to watch on Aug 31
31/08/2026 07:21
Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
31/08/2026 07:16
Spanish stocks - Factors to watch on July 28
28/07/2026 07:08